Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

February, 2016

All the posts published.

Wanda and Dignity Health launch OncoVerse platform

Feb 29, 2016
-
News, RNS Announcements, Wanda Health

RNS Number : 3883Q NetScientific PLC 29 February 2016 NetScientific plc Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform – OncoVerse™ London, UK – 29 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of …

NetScientific appoints Prof. Stephen Smith as NED

Feb 17, 2016
-
News, RNS Announcements

RNS Number : 2646P NetScientific PLC 17 February 2016 NetScientific plc   NetScientific appoints Professor Stephen Smith as Non-Executive Director   London, UK – 17 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees. …

PDS Biotechnology partners with NCI

Feb 9, 2016
-
News, PDS Biotechnology, RNS Announcements

RNS Number : 5158O NetScientific PLC 09 February 2016   NetScientific plc PDS Biotechnology partners with National Cancer Institute in Phase II clinical trials for novel cancer immunotherapies London, UK – 9 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, is pleased to note that one of its portfolio companies, PDS Biotechnology, has signed …

Grant of Options to Director

Feb 8, 2016
-
News, RNS Announcements

RNS Number : 4149O NetScientific PLC 08 February 2016 NetScientific plc   Grant of Options to Director   London, UK – 8 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group today announced that on 4 February 2016, options over a total of 200,000 ordinary shares of 5p each were granted to Francois Martelet.   Director …

February 2016 - NetScientific